Skip to main content
Erschienen in: Supportive Care in Cancer 5/2024

01.05.2024 | Research

Multidisciplinary analysis of cancer-related fatigue at the time of diagnosis: preliminary results of the BIOCARE FActory cohort

verfasst von: A. Leclercq, A. Chatrenet, H. Bourgeois, O. Cojocarasu, C. Mathie, T. Martin, A. Rahmani, B. Morel

Erschienen in: Supportive Care in Cancer | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cancer-related fatigue (CRF) is a common side effect of cancer and cancer treatment that significantly impairs the quality of life and can persist for years after treatment completion. Although fatigue is often associated with cancer treatment, it is also a result of the disease itself, even before intervention. CRF at the time of diagnosis may affect treatment timing or completion and is a consistent predictor of post-treatment fatigue at any time. The mechanisms underlying CRF are multidimensional and not well understood, particularly at the time of diagnosis.

Methods

Sixty-five breast cancer patients at the time of diagnosis were included. The participants completed self-assessment questionnaires about CRF, sleep disturbances, and emotional symptoms and wore an accelerometer to assess levels of spontaneous physical activity and sleep quality. During the experimental session, the participants underwent cognitive, neuromuscular, and exercise metabolism evaluations.

Results

Using augmented backward elimination regression, this study found that emotional symptoms and perceived sleep disturbances were the strongest predictors of CRF (adjusted r2 = 0.51). Neuromuscular fatigability and sleep disturbance were also associated with physical dimensions, whereas cognitive performance was associated with cognitive dimensions.

Conclusion

At the time of diagnosis, emotional and cognitive dimensions are over-represented compared to the general population, and specific subdimensions have specific predictors that support the idea of distinct mechanisms. Evaluating CRF subdimensions and their potential mechanisms at the time of diagnosis would be particularly relevant for identifying high-risk patients and offering them appropriate interventions.

Trial registration

This study was registered at ClinicalTrials.gov (NCT04391543) in May, 2020.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
10.
Zurück zum Zitat Pendergrass J, Targum S, Harisson J (2018) Cognitive impairment associated with cancer: a brief review. Innov Clin Neurosci 15:36–44PubMedPubMedCentral Pendergrass J, Targum S, Harisson J (2018) Cognitive impairment associated with cancer: a brief review. Innov Clin Neurosci 15:36–44PubMedPubMedCentral
27.
Zurück zum Zitat Friedrich M, Nowe E, Hofmeister D et al (2018) Psychometric properties of the fatigue questionnaire EORTC QLQ-FA12 and proposal of a cut-off value for young adults with cancer. Health Qual Life Outcomes 16:1–11CrossRef Friedrich M, Nowe E, Hofmeister D et al (2018) Psychometric properties of the fatigue questionnaire EORTC QLQ-FA12 and proposal of a cut-off value for young adults with cancer. Health Qual Life Outcomes 16:1–11CrossRef
32.
Zurück zum Zitat Tréhout M, Leroux E, Bigot L et al (2021) A web-based adapted physical activity program (e-APA) versus health education program (e-HE) in patients with schizophrenia and healthy volunteers: study protocol for a randomized controlled trial (PEPSY V@Si). Eur Arch Psychiatry Clin Neurosci 271:325–337. https://doi.org/10.1007/s00406-020-01140-zCrossRefPubMed Tréhout M, Leroux E, Bigot L et al (2021) A web-based adapted physical activity program (e-APA) versus health education program (e-HE) in patients with schizophrenia and healthy volunteers: study protocol for a randomized controlled trial (PEPSY V@Si). Eur Arch Psychiatry Clin Neurosci 271:325–337. https://​doi.​org/​10.​1007/​s00406-020-01140-zCrossRefPubMed
35.
Zurück zum Zitat Denise P, Benoît O (2016) Actisomm. Logiciel d’analyse des données actimétriques Denise P, Benoît O (2016) Actisomm. Logiciel d’analyse des données actimétriques
45.
Zurück zum Zitat Association AP, Association AP (2013) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DCCrossRef Association AP, Association AP (2013) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DCCrossRef
46.
Zurück zum Zitat Chand SP, Marwaha R (2023) Anxiety. In: StatPearls. StatPearls Publishing Chand SP, Marwaha R (2023) Anxiety. In: StatPearls. StatPearls Publishing
Metadaten
Titel
Multidisciplinary analysis of cancer-related fatigue at the time of diagnosis: preliminary results of the BIOCARE FActory cohort
verfasst von
A. Leclercq
A. Chatrenet
H. Bourgeois
O. Cojocarasu
C. Mathie
T. Martin
A. Rahmani
B. Morel
Publikationsdatum
01.05.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 5/2024
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-024-08520-4

Weitere Artikel der Ausgabe 5/2024

Supportive Care in Cancer 5/2024 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.